AbbVie to expand immunology pipeline with Nimble Therapeutics acquisition
In a significant move to solidify its presence in immunology, AbbVie has announced the acquisition of Nimble Therapeutics, a company at the forefront of peptide-based ... Read More
Genmab’s epcoritamab therapy delivers promising results for relapsed follicular lymphoma
Relapsed or refractory follicular lymphoma (FL) remains a persistent challenge for patients, particularly those with high-risk features. Genmab A/S, alongside its development partner AbbVie, announced ... Read More
AbbVie’s schizophrenia treatment crumbles, boosting Bristol Myers Squibb to the top
Bristol Myers Squibb's stock surged dramatically after pharmaceutical giant AbbVie announced disappointing results in its recent clinical trials for a promising schizophrenia drug. The development ... Read More
AbbVie makes bold move in Alzheimer’s market with $1.4bn Aliada buyout—Is it a gamble?
AbbVie, the renowned American biopharmaceutical giant, is set to acquire Aliada Therapeutics for a staggering $1.4 billion. The acquisition grants AbbVie control over Aliada’s promising ... Read More
NImmune Biopharma collaborates with BioTherapeutics on next-gen precision medicines
NImmune Biopharma has entered into a strategic partnership with BioTherapeutics, a clinical-stage biotech company based in Virginia, to accelerate the development of next-generation precision medicines ... Read More
AbbVie and Genmab’s TEPKINLY approved by EC for advanced lymphoma
AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB) have announced that the European Commission (EC) has granted conditional marketing authorization for TEPKINLY (epcoritamab), a groundbreaking therapy ... Read More
AbbVie acquires Celsius Therapeutics to enhance inflammatory disease treatment options
In a significant move within the biotechnology industry, AbbVie Inc. (NYSE: ABBV), a global biopharmaceutical company, has completed the acquisition of Celsius Therapeutics, Inc., a ... Read More
AbbVie’s SKYRIZI wins FDA approval for ulcerative colitis treatment
The U.S. Food and Drug Administration (FDA) has approved SKYRIZI (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor developed by AbbVie, for the treatment of adults with moderately ... Read More
AbbVie, FutureGen joins forces to pioneer next-gen IBD treatment FG-M701
In a significant development in the pharmaceutical industry, AbbVie Inc. (NYSE: ABBV) and FutureGen Biopharmaceutical (Beijing) Co., Ltd. have entered into a licensing agreement to ... Read More
AbbVie reports positive long-term results for atogepant in migraine prevention
AbbVie Inc. (NYSE: ABBV) has announced encouraging findings from an interim analysis of a 156-week extension study, assessing the long-term safety and effectiveness of atogepant, ... Read More